The PLA code reimbursement announcement is due at any moment (October/November 2024) according to recent updates on the matter (as per below screenshot).
A recent article (as per below image) discussed the positive potential of achieving this cost reimbursement and stated: "if there is a positive incentive for adoption such as the clinician getting paid then they will use the product."
Microbial resistance to antibiotics (AMR) is a real, present and global problem which is being fought on a global scale by pretty much all gov of the world. FebriDx can be a significant tool in the fight against AMR. IMO it is highly likely that the PLA code reimbursement will be granted as a contributing measure in the global fight against AMR.
Then comes the CLIA waiver (as per below image).!
IMO, LDX has a coherent plan which they appear to be executing in a systematic way.
IMO, some weak hands fail to understand this.....so let them sell and exit and lets get some more stoic investors on the register. Meanwhile, im happy to keep topping up. =)
Recent Article Discussing PLA Code ReimbursementCLIA Waiver
Add to My Watchlist
What is My Watchlist?
